HUMAN RECOMBINANT PAC1 RECEPTOR
MULTISCREEN™ DIVISION-ARRESTED CELL LINE
1 vial (2 x 106) frozen cells
Cellbanker 2 (Amsbio)
Full-length Human ADCYAP1R1 cDNA (GenBank Accession Number NM_001118.3) with FLAG-tag sequence at the N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS
Background: VIPR1 (Vasoactiveintestinalpolypeptidereceptor1) is also known as PACAP type II receptor (pituitary adenylate cyclase activating polypeptide type II receptor). It is a receptor for both vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide, and therefore more popularly known as VPAC1. VIP is a neuromodulator and growth regulator in the developing nervous system. Both VIPR1 and VIPR2 are highly expressed in central primitive neuroectodermal tumors and mediate the growth modulation of VIP in these tumors. VIPR1 gene is mapped to human 3p22-p21 where loss-of-heterozygosity is observed in small-cell lung carcinoma (SCLC) cell lines and primary tumors.
Application: Functional assays
Figure 1. Dose-dependent stimulation of intracellular cAMP accumulation upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01).
Karacay et al. (2001) Expression and fine mapping of murine vasoactive intestinal peptide receptor 1. J Mol Neurosci 17:311-324.
Fruhwald et al. (1999) Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int J Cancer 81:165-173.